Abingworth appoints Robert DeBenedetto as Managing Director in September 2024
- Robert DeBenedetto has been appointed as Managing Director for Clinical Co-Development at Abingworth, effective September 10, 2024.
- He brings over 30 years of experience in the life sciences industry, previously serving as CEO of SFJ Pharmaceuticals, where he led the development of multiple therapeutics.
- His appointment is expected to enhance Abingworth's ability to execute Clinical Co-Development deals and strengthen its investment strategies.
On September 10, 2024, Abingworth, a prominent life sciences investment firm, announced the appointment of Robert (Bob) DeBenedetto as Managing Director for Clinical Co-Development. With over 30 years of experience in the life sciences sector, Bob will focus on executing Clinical Co-Development deals with both new and existing portfolio companies from Abingworth's Menlo Park, CA office. His previous role as Founder, President, and CEO of SFJ Pharmaceuticals, an Abingworth portfolio company, highlights his expertise in this area. Bob's leadership at SFJ Pharmaceuticals has been significant, as he played a crucial role in the global development and approval of various therapeutics, including oncology drugs and treatments for rare diseases. His extensive background includes senior positions at Quintiles, Boston Scientific, and EY, showcasing a well-rounded career in the industry. Additionally, he serves on the boards of SFJ Pharmaceuticals and the Smithsonian Institution, further emphasizing his influence in the field. Kurt von Emster, Managing Partner & Head of Abingworth Life Sciences, expressed confidence in Bob's ability to enhance the firm's capabilities in sourcing and executing future deals. This appointment is expected to strengthen Abingworth's position in the life sciences investment landscape, particularly in Clinical Co-Development, which has seen significant growth. Abingworth has successfully raised over $1 billion across three Clinical Co-Development funds and invested in 16 programs, demonstrating its commitment to advancing innovative therapies. Bob's addition to the team is anticipated to bolster these efforts and drive further success in the firm's investment strategies.